EA202190308A1 - Применение пролекарств рилузола для лечения болезни альцгеймера - Google Patents

Применение пролекарств рилузола для лечения болезни альцгеймера

Info

Publication number
EA202190308A1
EA202190308A1 EA202190308A EA202190308A EA202190308A1 EA 202190308 A1 EA202190308 A1 EA 202190308A1 EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A1 EA202190308 A1 EA 202190308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
riluzole
disease
alzheimer
drugs
treatment
Prior art date
Application number
EA202190308A
Other languages
English (en)
Russian (ru)
Inventor
Владимир Корик
Роберт Берман
Ирфан Куреши
Original Assignee
Биохэйвен Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэйвен Терапьютикс Лтд. filed Critical Биохэйвен Терапьютикс Лтд.
Publication of EA202190308A1 publication Critical patent/EA202190308A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA202190308A 2018-07-22 2019-07-20 Применение пролекарств рилузола для лечения болезни альцгеймера EA202190308A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
EA202190308A1 true EA202190308A1 (ru) 2021-05-19

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190308A EA202190308A1 (ru) 2018-07-22 2019-07-20 Применение пролекарств рилузола для лечения болезни альцгеймера

Country Status (14)

Country Link
US (1) US12161633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530543A (cg-RX-API-DMAC7.html)
KR (1) KR20210034621A (cg-RX-API-DMAC7.html)
CN (1) CN112469408A (cg-RX-API-DMAC7.html)
AU (1) AU2019310013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107215A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190308A1 (cg-RX-API-DMAC7.html)
IL (1) IL280177B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000515A (cg-RX-API-DMAC7.html)
PH (1) PH12021550043A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100385YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US10751345B2 (en) * 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Also Published As

Publication number Publication date
AU2019310013B2 (en) 2025-01-02
WO2020023324A1 (en) 2020-01-30
MX2021000515A (es) 2021-06-08
SG11202100385YA (en) 2021-02-25
IL280177A (en) 2021-03-01
IL280177B1 (en) 2024-09-01
CA3107215A1 (en) 2020-01-30
JP2021530543A (ja) 2021-11-11
EP3823616A1 (en) 2021-05-26
EP3823616A4 (en) 2022-05-04
NZ772009A (en) 2026-02-27
BR112021000768A2 (pt) 2021-05-11
AU2019310013A1 (en) 2021-02-11
PH12021550043A1 (en) 2021-09-20
KR20210034621A (ko) 2021-03-30
US12161633B2 (en) 2024-12-10
CN112469408A (zh) 2021-03-09
MX2024010655A (es) 2024-09-11
IL280177B2 (en) 2025-01-01
US20210290599A1 (en) 2021-09-23
JP2025093952A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
NZ777871A (en) Small molecule modulators of il-17
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
PH12021550443A1 (en) Pyridazinones and methods of use thereof
JOP20190191A1 (ar) وحدات شجرية علاجية
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
ZA202002626B (en) Use of riluzole prodrugs to treat ataxias
EA201790315A1 (ru) Модуляторы x-рецепторов печени
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
MX382357B (es) Métodos y composiciones para tratar infecciones fúngicas cutáneas.
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
EA202190406A1 (ru) Способы лечения нейродегенеративных расстройств
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA202091162A1 (ru) Применение пролекарств рилузола для лечения атаксии